BICO (Q3 Initial take): Solid margins and cost control with slightly lower sales than expected - Redeye

BICO (Q3 Initial take): Solid margins and cost control with slightly lower sales than expected - Redeye

Redeye provides an initial take following the release of BICO's Q3 2026 report. Sales came in slightly below our estimate, but a strong gross margin and continued cost control drove adjusted EBITDA well ahead of our expectations. The quarter was flattered by a one-off contribution of SEK135m from the SCIENION supply and license agreements, while EBIT was weighed down by a non-cash impairment of the remaining Biosero goodwill and technology. Alongside the report, BICO launched its new BICO 2030 strategy, which formalises a step away from large-scale integrated lab automation projects and a sharper focus on Precision Biology.

Länk till analysen i sin helhet: https://www.redeye.se/research/1192530/bico-q3-initial-take-solid-margins-and-cost-control-with-slightly-lower-sales-than-expected?utm_source=finwire&utm_medium=RSS